MediPharm Labs Statistics
Total Valuation
MediPharm Labs has a market cap or net worth of 21.72 million. The enterprise value is 13.79 million.
| Market Cap | 21.72M |
| Enterprise Value | 13.79M |
Important Dates
The next estimated earnings date is Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 424.86M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.10% |
| Shares Change (QoQ) | +1.30% |
| Owned by Insiders (%) | 9.16% |
| Owned by Institutions (%) | 0.00% |
| Float | 385.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.66 |
| PB Ratio | 0.80 |
| P/TBV Ratio | 0.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.39 |
| EV / Sales | 0.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.69 |
Financial Position
The company has a current ratio of 3.20, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.20 |
| Quick Ratio | 2.18 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | -101.18 |
Financial Efficiency
Return on equity (ROE) is -19.36% and return on invested capital (ROIC) is -23.19%.
| Return on Equity (ROE) | -19.36% |
| Return on Assets (ROA) | -8.03% |
| Return on Invested Capital (ROIC) | -23.19% |
| Return on Capital Employed (ROCE) | -17.37% |
| Weighted Average Cost of Capital (WACC) | 8.20% |
| Revenue Per Employee | 205,587 |
| Profits Per Employee | -35,785 |
| Employee Count | 161 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 3.79 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.89% in the last 52 weeks. The beta is 0.71, so MediPharm Labs's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | +14.89% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 54.82 |
| Average Volume (20 Days) | 96,429 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MediPharm Labs had revenue of 33.10 million and -5.76 million in losses. Loss per share was -0.01.
| Revenue | 33.10M |
| Gross Profit | 10.02M |
| Operating Income | -4.72M |
| Pretax Income | -5.76M |
| Net Income | -5.76M |
| EBITDA | -3.48M |
| EBIT | -4.72M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 8.10 million in cash and 303,685 in debt, with a net cash position of 7.80 million.
| Cash & Cash Equivalents | 8.10M |
| Total Debt | 303,685 |
| Net Cash | 7.80M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 27.18M |
| Book Value Per Share | 0.06 |
| Working Capital | 13.78M |
Cash Flow
In the last 12 months, operating cash flow was -5.03 million and capital expenditures -103,382, giving a free cash flow of -5.13 million.
| Operating Cash Flow | -5.03M |
| Capital Expenditures | -103,382 |
| Free Cash Flow | -5.13M |
| FCF Per Share | n/a |
Margins
Gross margin is 30.28%, with operating and profit margins of -14.27% and -17.41%.
| Gross Margin | 30.28% |
| Operating Margin | -14.27% |
| Pretax Margin | -17.41% |
| Profit Margin | -17.41% |
| EBITDA Margin | -10.50% |
| EBIT Margin | -14.27% |
| FCF Margin | n/a |
Dividends & Yields
MediPharm Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.10% |
| Shareholder Yield | -4.10% |
| Earnings Yield | -26.53% |
| FCF Yield | -23.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediPharm Labs has an Altman Z-Score of -2.52 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.52 |
| Piotroski F-Score | 2 |